![Tracy Palmer Berns](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tracy Palmer Berns
Keine laufenden Positionen mehr
Karriereverlauf von Tracy Palmer Berns
Ehemalige bekannte Positionen von Tracy Palmer Berns
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Compliance Officer | 29.06.2020 | - |
AMAG PHARMACEUTICALS, INC. | Compliance Officer | 29.09.2017 | - |
Ausbildung von Tracy Palmer Berns
Knox College | Undergraduate Degree |
Columbia Law School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Compliance Officer | 2 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
AMAG Pharmaceuticals, Inc.
![]() AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Akcea Therapeutics, Inc.
![]() Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Tracy Palmer Berns
- Erfahrung